G9a decreases Rhox5 expression. by Mayumi Sugimoto (151133)

G9a decreases Rhox5 expression. by Mayumi Sugimoto (151133)

Administration of APB5, but not APA5, decreases the hyperplasia of alveolar type 2 epithelial cells induced by BLM. by Masami Kishi (6167105)

“…The administration of APB5 markedly decreased the hyperplasia of type 2 epithelial cells induced by BLM. …”

Vi expression decreases antibody and complement binding to <i>Salmonella</i> in the absence of specific antibodies. by Peter J. Hart (503558)

Mice exposed to neonatal hyperoxia have persistent RVH and decreased vessel density at 21d. by Marta Perez (526067)

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Illustration of the predicted mean (n = 10) twist along the carpal tunnel in neutral and with combined FE and RUD postures. by Drew A. Anderson (14197446)

Subjects:

TG mice hearts show decreased ISO response. by Mayilvahanan Shanmugam (691549)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. by Nicoletta Loberto (2224150)

Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

“…<p>(A) A375 and (B) MeWo melanoma cells were treated with 0.5 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for 24 h, 48 h, or 72 h and analyzed for cell viability by the MTT method (* significant relative to control; p<0.05; N = 4). …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

TG6-44 treatment leads to decrease in A/X31-induced cell death in THP-1 cells. by Juan A. De La Cruz (11154187)

Quantitation of the decrease in viability of schistosomula caused by GSK343 treatment at different concentrations and incubation times. by Adriana S. A. Pereira (5900249)

Predicting alternans in the V_m-driven model during a progressive decrease of I_Ks conductance. by Mathieu Lemay (330649)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”